Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.
Por:
Sidana, S, Martinez-Lopez, J, Khan, AM, Oriol, A, Spencer, A, Dhakal, B, Cohen, YC, Touzeau, C, Dytfeld, D, Einsele, H, San-Miguel, J, Manier, S, Chen, Y, Li, K, Benachour, N, Lonardi, C, Ghosh, A, Patel, N, Florendo, E and Harrison, SJ
Publicada:
1 jun 2025
Resumen:
Filiaciones:
Stanford Univ, Sch Med, Stanford, CA USA
Univ Complutense Madrid, Hosp Octubre 12, MIC, CNIO, Madrid, Spain
Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
Inst Catala Oncol, Barcelona, Spain
Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain
Monash Univ, Alfred Hlth, Melbourne, Vic, Australia
Med Coll Wisconsin, Milwaukee, WI USA
Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
Ctr Hosp Univ CHU Hotel Dieu, Serv Hematol, Nantes, France
Poznan Univ Med Sci, Poznan, Poland
Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
Univ Navarra, CIMA, IDISNA, Canc Ctr Clin, Pamplona, Spain
Univ Lille, CHU Lille, Lille, France
Johnson &Johnson, Shanghai, Peoples R China
Johnson & Johnson, Spring House, PA USA
Johnson & Johnson, Beerse, Belgium
Johnson & Johnson, Buenos Aires, Argentina
Johnson & Johnson, Raritan, NJ USA
Legend Biotech USA Inc, Somerset, NJ USA
Peter MacCallum Canc Ctr, Melbourne, Australia
Royal Melbourne Hosp, Melbourne, Australia
Bronze
|